Exagen (XGN)
(Delayed Data from NSDQ)
$1.41 USD
0.00 (0.15%)
Updated Apr 26, 2024 03:50 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
Price, Consensus and EPS Surprise
XGN 1.41 0.00(0.15%)
Will XGN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for XGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for XGN
Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates
Cresco Labs Inc. (CRLBF) Q4 Earnings and Revenues Surpass Estimates
XGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zynex Inc. (ZYXI) Q4 Earnings and Revenues Miss Estimates
Despite Fast-paced Momentum, Exagen Inc. (XGN) Is Still a Bargain Stock
Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates
Other News for XGN
Exagen Inc. Announces Changes to the Board of Directors
Exagen Inc Board Reshuffle and New Class I Director Appointment
Exagen to reduce size of board to seven from nine
Wall Street Analysts Are Bullish on Top Healthcare Picks
Buy Rating Affirmed for Exagen on Strong Financials and Strategic Growth Initiatives